Project Grant R01HL180711
Award Date 9/1/25
Completion Date 6/30/29
Dollars Obligated $676K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Illinois, USA
Similar Awards
- The University of Arizona was awarded a $735,838 project grant by the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) on July 15, 2025. The grant supports research into the role of hexokinase 1 (HK1) mitochondrial dislocation in the development of heart failure with preserved ejection fraction (HFpEF). The key objectives are to investigate how HK1 dislocation leads to increased protein O-GlcNAcylation in cardiac endothelial cells, and to assess...
- This Project Grant award of $576,786.00, provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), supports research at the University of Arizona to investigate the role of the YTHD2 protein in regulating the translation of the NRF2 protein under conditions of oxidative stress. The research aims to elucidate the mechanisms by which certain proteins, like NRF2, can continue to be translated despite the general inhibition of protein...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $771,750 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of California, Los Angeles (UCLA) to investigate the role of macrophages in regulating cardiac muscle metabolism after myocardial infarction. The project aims to shed novel insights into how macrophages recruited to the infarcted heart disrupt cardiac muscle metabolism and lead to decreased NAD pools, which play a critical...
- The University of Arizona was awarded a $625,316 Project Grant from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to investigate the role of RNA methylation and translational regulation in the oxidative stress response of heart failure. The research aims to elucidate how the YTHDF2 protein binds to methylated NRF2 mRNA to selectively induce its translation under oxidative stress, a process that may be impaired in end-stage heart failure. The...
- This federal Project Grant award of $621,546.00, provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), focuses on observing the single molecule dynamics of the catalytic subunit of cAMP-dependent protein kinase A (PKA-C) under both normal and disease-associated conditions. The primary objectives are to: 1) Engineer a single-walled carbon nanotube field effect transistor (SWNT FET) system to record PKA-C single molecule...
- This $651,967 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to elucidate the role of cardiac tissue-resident macrophages in heart failure progression. The principal investigator at the Texas Heart Institute will conduct research over a 5-year period from August 2025 to May 2030 to determine how macrophage senescence contributes to cardiomyocyte dysfunction, inflammation, and impaired clearance of cellular debris in...
- This federal Project Grant award of $605,253 from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research by the University of Delaware to investigate the protective role of cardiac HSP90β ablation/inhibition for mitigating myocardial infarction and ischemia-reperfusion injury. The research aims to thoroughly examine if cardiac-specific HSP90β knockout confers cardioprotection, potentially by preserving mitochondrial membrane integrity....
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) to the University of Louisville for $108,030.00 supports research on the role of emergency granulopoiesis in wound healing after myocardial infarction. The key objectives are to determine if myocardial infarction-induced emergency granulopoiesis gives rise to neutrophils with differential function, and if emergency granulopoiesis contributes to post-myocardial infarction...
- The University of Arizona, operating as the Arizona Board of Regents, was awarded a $125,385 Project Grant on June 15, 2025 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to investigate the role of mutation-specific calmodulin kinase II (CaMKIID) activation in hypertrophic cardiomyopathy (HCM). The project aims to elucidate the specific biophysical alterations in the cardiac thin filament that trigger increased autonomous CaMKIID activity in...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $618,045 to the University of Arizona to conduct research on identifying new mechanisms and targets for treating diastolic dysfunction in hypertrophic cardiomyopathy (HCM). The primary objectives are to: 1) fully characterize at the atomic level three specific functional domains of the cardiac thin filament linked to the...